Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
about
EGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell LineMultiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastomaA new aurora in anaplastic thyroid cancer therapy.Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis.Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cellsAccess to the nucleus and functional association with c-Myc is required for the full oncogenic potential of ΔEGFR/EGFRvIIICombination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo.Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer.Epidermal growth factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1.A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.EGF stimulates glioblastoma metastasis by induction of matrix metalloproteinase-9 in an EGFR-dependent mechanism.Identification of a novel fusion gene HMGA2-EGFR in glioblastoma.FHL2 interacts with EGFR to promote glioblastoma growth.Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment.EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
P2860
Q28551853-CD967A80-8FEE-4692-822C-F4C925E78F59Q30405446-377F66A4-5F87-406E-881E-A6C3981A6412Q33930368-8ED61531-828B-42C6-B630-79DB24E60900Q34154786-44C4ED8E-76C5-4077-8D22-DE42CE1A000DQ35091330-B470DAE1-AB7B-44BD-8EC9-C0089ABCF1C2Q36113481-5A26362C-6612-40CF-9C84-E29EA9872020Q36214610-5AD63B74-671A-4D08-AE30-83AFCF4C5BA2Q36579570-1B7FB37B-097D-4F78-9928-25AC9AC5EFB3Q37269431-5B53BEAB-466C-4CF8-980F-B89F891206AEQ37362563-AF87BCAE-334C-47DF-B7E1-0064A100E484Q37452081-AD3D9847-7D23-4A4A-8FAA-EB68F8D59FB5Q38928014-EB8FEB7B-3051-416D-BBE4-1C2EC1AA7C54Q39168444-0692FB57-F831-463A-911E-2A55147A95EFQ42371599-38048C63-1F63-4D7A-909E-F9D74AFC3F8BQ47343878-04CEC42E-631E-4E91-AF66-09170F66FECBQ47871595-EA06C034-7D03-4E90-8CE5-CCB8D91D6E37Q50100856-40F4F265-E0D0-4C1F-921D-CBCFEF1B7CF7Q55271166-8ACA4EEB-21BB-44B5-BE4E-A0C36DC0394BQ55457200-21081CB6-F7BB-4345-8FFF-F1047A37C7C6
P2860
Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Nuclear EGFRvIII-STAT5b comple ...... vation of the Bcl-XL promoter.
@ast
Nuclear EGFRvIII-STAT5b comple ...... vation of the Bcl-XL promoter.
@en
type
label
Nuclear EGFRvIII-STAT5b comple ...... vation of the Bcl-XL promoter.
@ast
Nuclear EGFRvIII-STAT5b comple ...... vation of the Bcl-XL promoter.
@en
prefLabel
Nuclear EGFRvIII-STAT5b comple ...... vation of the Bcl-XL promoter.
@ast
Nuclear EGFRvIII-STAT5b comple ...... vation of the Bcl-XL promoter.
@en
P2093
P2860
P356
P1476
Nuclear EGFRvIII-STAT5b comple ...... vation of the Bcl-XL promoter.
@en
P2093
Anupama Gururaj
Kenneth Aldape
Khatri Latha
Raymond Sawaya
Sumana Dakeng
Vaibhav Chumbalkar
Webster K Cavenee
YeoHyeon Hwang
P2860
P304
P356
10.1002/IJC.27690
P577
2012-07-09T00:00:00Z